Viewray Stock News

CLEVELAND , July 19, 2022 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today details relating to the release of its first quarter 2022 financial results. ViewRay will hold a conference call

ViewRay (VRAY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

ViewRay, Inc. (NASDAQ:VRAY ) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants Matt Harrison - Director, Investor Relations Scott Drake - President and CEO Zach Stassen - Ch

ViewRay (VRAY) delivered earnings and revenue surprises of 12.50% and 13.55%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

ViewRay Inc (NASDAQ: VRAY ) has announced the first toxicity results from the Phase 2 SCIMITAR trial assessing stereotactic body radiation therapy (SBRT) in prostate cancer patients who have undergone surgery. The first toxicity results evaluated 100 patients with recurrent prostate cancer after radical prostatectomy. The patients underwent SBRT delivered under either CT guidance or MRI guidance. The data found that … Full story available on Benzinga.com

ViewRay (VRAY) said a interim toxicity results from a phase 2 trial suggest favorable toxicity profile of post-prostatectomy stereotactic body radiotherapy ((SBRT)) for prostate…

VRAY earnings call for the period ending December 31, 2021.

ViewRay, Inc. (VRAY) CEO Scott Drake on Q4 2021 Results - Earnings Call Transcript

ViewRay press release (VRAY): Q4 GAAP EPS of -$0.16 misses by $0.02.Revenue of $20.4M (+10.5% Y/Y) beats by $0.67M.ViewRay had total cash and cash equivalents of $218.3 million…

CLEVELAND, Feb. 24, 2022 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) (the "Company") today announced financial results for the fourth quarter and full fiscal year ended December 31, 2021. Full Year 2021 Highlights Total revenue of $70.1 million primarily from ten revenue units, compared…

ViewRay (VRAY) delivered earnings and revenue surprises of -6.67% and 2.76%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

ViewRay (NASDAQ:VRAY) is scheduled to announce Q4 earnings results on Thursday, February 24th, after market close.The consensus EPS Estimate is -$0.15 (+16.7% Y/Y) and the consensus…

ViewRay Inc (NASDAQ: VRAY ) has announced interim data from the single-center Phase 3 MIRAGE trial comparing MRIdian MRI-guided vs. CT-guided SBRT for localized prostate cancer. The data will be featured at the 2022 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium. Interim analysis … Full story available on Benzinga.com